Spots Global Cancer Trial Database for Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL
Official Title: Safety, Efficacy and a Simple Model to Predict Response of BNT162b2 mRNA
Study ID: NCT04862806
Conditions
Interventions
Study Description
Brief Summary: On behalf of the Israel CLL study group the investigators will evaluate the efficacy and safety of BNT162b2 mRNA Covid-19 Vaccine in patients with chronic lymphocytic leukemia
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Bnai Zion Medical Center, Haifa, , Israel
Hematology Division, Chaim Sheba Medical Center, Tel Aviv, , Israel
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
